The United states center for disease control (CDC) approves a first ever vaccine against severe respiratory syncytial virus (RSV) disease. 

RSV is one of the most common causes of childhood respiratory sickness and the cause of death for 100 to 300 US children under the age of five per year. 

CDC found that use of the long-acting monoclonal antibody Nirsevimab, tradename BeyfortusTM, reduced the incidence of both hospitalizations and doctor visits for RSV in newborns by nearly 80%. 

CDC recommends single dose of Nirsevimab for all under 8 months, for their first RSV season and additional dose for immunocompromised children between the ages of 8 and 19 months.